Pharmacokinetic (PK) model generated based on the single ascending dose (SAD) data and the first multiple ascending dose (MAD ...

The Phase 1 (ACTRN12625000212459p) randomized, double-blind, placebo-controlled, first-in-human study of single ascending doses of ABS-101 will evaluate safety, tolerability, pharmacokinetics (PK), ...

The following is a summary of “Model-informed identification of optimised dosing strategies for meropenem in critically ill ...

Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid’s first program in its KCC2 direct activator library, OV350, ...

On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – – Plans to ...

The City of Geneva Police Department posted a ‘quick-fact’ sheet to its Facebook page over the weekend which included the ...

Pasithea shares rise as early Phase 1 data of PAS-004 shows strong pERK inhibition and tumor shrinkage in advanced cancer ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in ...

At the recent SEC meeting for endocrinology and metabolism held on 25th March 2025, the expert panel reviewed the proposal of ...

Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, I ...

On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 - - Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer's disease ...

Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approval "In the first quarter of 2025, we achieved a major milestone for Aquestive with the submission ...